CSF2 and glioblastoma: In the SurVaxM trial for glioblastoma, vaccination was experimentally combined with fixed doses of recombinant granulocyte macrophage-colony stimulating factor (GM-CSF), a commonly used immunomodulator (184), demonstrating safety and favorable T-cell immune responses.